OU Health Stephenson Cancer Center joins Caris’ Precision Oncology Alliance

Lei Zheng named executive director of Mays Cancer Center

Lei Zheng was named executive director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, and vice president for oncology for the University of Texas Health Science Center at San Antonio.

July 12, 2024

Vol.50 No.28

In Brief

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.

July 12, 2024

Vol.50 No.28

Drugs & Targets

Parexel releases report on advancing precision oncology

Parexel, one of the world’s largest clinical research organizations providing the full range of phase I to IV clinical development services, has released a new report in their expert series, New Medicines, Novel Insights.

May 24, 2024

Vol.50 No.21

Clinical Trials & Tribulations

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.

May 10, 2024

Vol.50 No.19

By Sanju Sinha and Eytan Ruppin

In Brief

Northwell opens molecular diagnostics laboratory to identify targeted cancer therapies

The Northwell Health Cancer Institute and its Center for Genomic Medicine opened Long Island’s first clinical Molecular Diagnostics Laboratory, a $3.2 million 2,800 square foot state-of-the-art facility with technology of next-generation sequencing that provides point-of-care tumor and patient genomic profiling to inform precision cancer therapy.

May 10, 2024

Vol.50 No.19

Clinical Roundup

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.

March 29, 2024

Vol.50 No.13

OU Health Stephenson Cancer Center joins Caris’ Precision Oncology Alliance

YOU MAY BE INTERESTED IN

Lei Zheng named executive director of Mays Cancer Center

Mark Burkard named director of UI Health Care Holden Comprehensive Cancer Center

Parexel releases report on advancing precision oncology

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Northwell opens molecular diagnostics laboratory to identify targeted cancer therapies

Observational study demonstrates clinical validity and utility of OncoHost’s PROphet NSCLC test

Renew today!

Subscriber content

Login